The fund is rated 0.5 stars. Investment selection within each industry provided some support. Investment selection within each asset type and balance between returns and downside risk were the main limitations and did not provide enough support for a higher rating. Higher annual fee of 2.12% and above-average fund size of Rs 3,501.37 crore were minor drawbacks.
This fund has a bad track record with Asset Selection/Timing, a ok track record with Stock Selection/Timing, a bad risk-reward ratio. It is important to note, however, that this fund has a 3501.368 AUM and a 2.12 expense ratio. Considering all these factors, we have rated this fund as 0.5 star.
आमचा स्कोअर दीर्घकालीन कामगिरी, जोखीम आणि सातत्य यांचे वजन करतो — फक्त मागील परतावे नाही.
5 Nov 2026 पर्यंत
31 Oct 2026 पर्यंत
30 Sep 2026 पर्यंत
| होल्डिंग | फंडाचा % | मूल्य | शेअर्स |
|---|---|---|---|
| Divi's Laboratories Ltd. | 9.39% | ₹328.63 Cr | 3,53,687 |
| Sun Pharmaceutical Industries Ltd. | 8.28% | ₹289.76 Cr | 15,95,093 |
| Others | 4.67% | ₹163.43 Cr | — |
| Alkem Laboratories Ltd. | 4.64% | ₹162.58 Cr | 3,14,859 |
| Cipla Ltd. | 4.15% | ₹145.37 Cr | 10,80,050 |
| Apollo Hospitals Enterprise Ltd. | 3.69% | ₹129.18 Cr | 1,58,200 |
| Torrent Pharmaceuticals Ltd. | 3.65% | ₹127.91 Cr | 2,66,486 |
| Max Healthcare Institute Ltd. | 3.61% | ₹126.42 Cr | 13,59,696 |
| Aster DM Quality Care Ltd. | 3.56% | ₹124.51 Cr | 17,86,027 |
| Lupin Ltd. | 3.55% | ₹124.15 Cr | 6,11,505 |
To generate long-term capital appreciation Investment predominantly in equity & equity related instruments of Pharma and healthcare companies.
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Exit load of 1%, if redeemed within 30 days.
म्युच्युअल फंड बाजार जोखमीच्या अधीन आहेत. सर्व योजना दस्तऐवज काळजीपूर्वक वाचा.
